Clinical Trial Update: Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura [NA]

View source ↗

Summary

This completed clinical trial update examines vaccine response following rituximab treatment in patients with chronic, severe immune thrombocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Rituxan (rituximab)

Snippet

Sponsor: Neufeld, Ellis J, MD, PhD | Conditions: Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenic Purpura | NA | Status: COMPLETED